Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2016)
✉ Email this page to a colleague
ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-10-21 |
| Court | District Court, D. New Jersey | Date Terminated | 2020-06-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Brian R. Martinotti |
| Jury Demand | None | Referred To | Joseph A. Dickson |
| Parties | ADAPT PHARMA OPERATIONS LIMITED | ||
| Patents | 9,211,253; 9,468,747; 9,561,177; 9,629,965; 9,775,838 | ||
| Attorneys | MICHAEL E. PATUNAS | ||
| Firms | Quinn Emanuel Uquhart & Sullival LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-11-06 | 128 | Construction and Prehearing Statement for U.S. Patent No. 9,775,838 by ADAPT PHARMA LIMITED, ADAPT PHARMA OPERATIONS…2016 30 June 2020 2:16-cv-07721 830 Patent None District Court, D. New Jersey | External link to document | |
| 2019-02-06 | 171 | Amended Invalidity Contentions for U.S. Patent Nos. 9,211,253; 9,68,747; 9,561,177;9,629,965; and 9,775,838…2016 30 June 2020 2:16-cv-07721 830 Patent None District Court, D. New Jersey | External link to document | |
| 2019-04-24 | 200 | of United States Patent Numbers 9,211,253 (“‘253 patent”) and 9,468,747 (“747 patent”), Claim 10 of the… ‘253 patent and ‘747 patent, and Claim 29 of United States Patent No. 9,629,965 (“‘965 patent”).’ The…the ‘253 patent, Claims 3 and 33 of the ‘747 patent, Claims 5 and 27 of United States Patent No. 9,561,177…actuation.” (‘253 patent at 50:65—67; ‘747 patent at 53:42—44). Elsewhere, the ‘253 patent specification …9,561,177 (“177 patent”), and Claims 1 and 22 of the ‘965 patent. They have since resolved their dispute | External link to document | |
| 2019-04-24 | 201 | about 100 ul" as used in United States Patent Numbers 9,211,253 and 9,468,747 requires no further construction…2016 30 June 2020 2:16-cv-07721 830 Patent None District Court, D. New Jersey | External link to document | |
| 2019-11-12 | 283 | Brief | longer-asserted U.S. Patent No. 9,211,253 (“the 253 patent”).1 For each patent, Nalox-1 filed one petition…Challenged Patent Prior Art Instituted? IPR2019-00685 9,211,253 … 9,211,253 Wang No IPR2019-00687 9,211,253 …administrative patent judges is tasked with reviewing the patentability of a previously issued patent. To request… the four patents-in- suit before this Court (U.S. Patent Nos. 9,468,747 (“the ’747 patent”), 9,561, | External link to document |
| 2020-06-05 | 342 | Order | States Patents held by Plaintiffs: (1) Claims 7 and 9 of United States Patent Number 9,468,747 (the …the “’747 Patent”) (TX-0001) 2; (2) Claim 4 of United States Patent Number 9,561,177 (the “’177 Patent…, 24, and 25 of United States Patent Number 9,629,965 (the “’965 Patent”) (TX-0003); and (4) Claims…, 33, and 38 of United States Patent Number 9,775,838 (the “’838 Patent) (TX-0004). 1 On… ’747 Patent are INVALID; and it is further ORDERED that Claim 4 of the ’177 Patent is INVALID | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
